Unrelated Donor, Cord Blood Grafts Yield Extended Survival in Older AML Patients

Allogeneic transplantation using either unrelated donor or cord blood grafts "can produce extended and even curative long-term survival" in patients over age 50 with AML in first complete remission, according to a study of 740 transplants reported to CIBMTR (Center for International Blood and Marrow Transplant Research) and Eurocord. Three-year survival of 8/8 unrelated donor, 7/8 unrelated donor, and cord blood transplant recipients were 43%, 37%, and 30%, respectively, and the difference in survival between 8/8 unrelated donor and cord blood was statistically significant (p=0.002). The researchers concluded that "allogeneic transplantation need not be withheld from older patients and for clinically suitable AML patients."

Weisdorf DJ, et al. Biol Blood Marrow Transplant